Despite announcing record annual revenues and a substantial order backlog, shares in the Czechoslovak Group (CSG) have been under significant pressure, recently hitting a 52-week low. The divergence between robust operational results and the stock’s performance is attributed to mounting investor apprehension over corporate governance and ongoing regulatory scrutiny, rather than the company’s core business activities.
Operational Strength Amid Market Skepticism
From a purely operational standpoint, the industrial and technology conglomerate is performing exceptionally. Fueled by heightened global demand for artillery ammunition and armored vehicles, CSG reported that its revenue for the 2025 fiscal year surged by nearly 72 percent to €6.7 billion. The company’s order book has expanded to an impressive €42 billion. To further secure its supply chains for defense systems, CSG is advancing its vertical integration strategy. In late March, the firm signed a preliminary agreement to acquire Polish wiring harness manufacturer DOMAR MS.
The Core of Investor Caution
The market’s unease primarily stems from two key areas. First, reports have emerged of a corruption investigation by a NATO agency focused on CSG’s Spanish subsidiary, Fabrica de Municiones de Granada (FMG). While management stated in mid-March that no evidence of wrongdoing had been uncovered, the cloud of uncertainty persists.
Second, questions regarding transparency have arisen following the company’s recent initial public offering. It appears that certain minority shareholdings were not fully disclosed in the prospectus, leading institutional investors to doubt the firm’s commitment to transparency. Further dampening shareholder sentiment are concerns about the execution of large framework contracts with Slovakia.
Should investors sell immediately? Or is it worth buying CSG?
Analyst Views and Financial Outlook
Major investment banks are maintaining a positive outlook on the stock, largely focusing on its strong operational prospects. Deutsche Bank recently initiated coverage with a “buy” recommendation and a price target of €35. JPMorgan advises an “overweight” position, citing robust fundamentals and sector demand, and assigns a fair value estimate of €40 per share.
For the current 2026 fiscal year, CSG’s management anticipates revenue will climb further to approximately €7.6 billion, with adjusted net profit expected to reach around €1.17 billion.
Market Performance Reflects the Dichotomy
The stark contrast between the company’s solid business and its legal and governance overhangs is clearly visible in its share price movement. Over the past 30 days, the equity has declined by more than 26 percent. It currently trades at €22.97, precisely at its 52-week low. Market observers suggest that until the regulatory investigations and transparency issues are fully resolved, the company’s operational strength is likely to remain a secondary consideration for investors.
Ad
CSG Stock: Buy or Sell?! New CSG Analysis from March 31 delivers the answer:
The latest CSG figures speak for themselves: Urgent action needed for CSG investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 31.
CSG: Buy or sell? Read more here...








